Summary Box: Lilly receives restraining order

: Amylin Pharmaceuticals Inc. said Thursday a federal court issued an injunction preventing drug development partner Eli Lilly and Co. from using the same sales force to sell an Amylin-developed type 2 diabetes treatment, Byetta, and Boehringer Ingelheim's Tradjenta.

REACTION: Lilly said it was disappointed in the decision but will comply with the order.

THE BIG PICTURE: Amylin and Lilly entered an agreement in 2002 to develop and sell Byetta. Lilly then entered a development deal with Boehringer in January. Amylin sued Lilly earlier this month, after regulators approved Tradjenta, but said it plans to keep working with Lilly.

SEARCH